SYRE NASDAQ
Spyre Therapeutics, Inc.
1W: +8.8%
1M: +7.0%
3M: +5.0%
YTD: +204.7%
1Y: +466.2%
3Y: +711.0%
5Y: -51.4%
$93.19
+3.26 (+3.63%)
Weekly Expected Move ±5.3%
$83
$88
$93
$98
$103
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (68)
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – Should You Buy?
Spyre draws new Overweight at J.P. Morgan on IBD potential
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
California State Teachers Retirement System Buys 5,683,670 Shares of Spyre Therapeutics, Inc. $SYRE
11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al
Allianz Asset Management GmbH Takes Position in Spyre Therapeutics, Inc. $SYRE
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
Biggest stock movers Wednesday: SYRE, INTU, SAP and more
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $101.42
Spyre Therapeutics (NASDAQ:SYRE) Trading 5.7% Higher – Still a Buy?
Spyre Therapeutics Announces Grants of Inducement Awards
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
10 mid-cap U.S. stocks with the strongest momentum grades
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday
Spyre Therapeutics GAAP EPS of -$0.74 misses by $0.05
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Organon & Co is the best performing healthcare stock in April
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $85.08 Consensus Target Price from Analysts
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
Spyre Therapeutics launches $300M public stock offering
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares
Scott Burrows Sells 7,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock
Sheldon Sloan Sells 7,958 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $60.67
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
VR Adviser Adds Over 1 Million Savara Shares
Spyre Therapeutics, Inc. $SYRE Shares Bought by B Group Inc.
DLD Asset Management LP Acquires New Position in Spyre Therapeutics, Inc. $SYRE
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics Announces Grants of Inducement Awards
Short Interest in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Drops By 13.5%
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
Spyre Therapeutics' CEO Sells 15,000 Shares
Spyre Therapeutics Announces Grants of Inducement Awards
Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock
Spyre Therapeutics: Validated Targets, Optimized Delivery
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Intech Investment Management LLC